Review




Structured Review

Genomics England connective disorder gene panel
Pathogenic / Likely pathogenic variants in <t> connective </t> tissue and related disorders gene panel and anamnesis of patients with cervical insufficiency.
Connective Disorder Gene Panel, supplied by Genomics England, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/connective disorder gene panel/product/Genomics England
Average 90 stars, based on 1 article reviews
connective disorder gene panel - by Bioz Stars, 2026-05
90/100 stars

Images

1) Product Images from "Unravelling the genetic landscape of cervical insufficiency: Insights into connective tissue dysfunction and hormonal pathways"

Article Title: Unravelling the genetic landscape of cervical insufficiency: Insights into connective tissue dysfunction and hormonal pathways

Journal: PLOS ONE

doi: 10.1371/journal.pone.0310718

Pathogenic / Likely pathogenic variants in  connective  tissue and related disorders gene panel and anamnesis of patients with cervical insufficiency.
Figure Legend Snippet: Pathogenic / Likely pathogenic variants in connective tissue and related disorders gene panel and anamnesis of patients with cervical insufficiency.

Techniques Used: Sequencing, RNA Expression

A) Expression (Y axis) of connective tissue disorder genes (blue) in relation to all genes showing at least some expression within cervix (TPM>0) (light blue) (X axis). B) Beighton (pink) / Brighton (blue) / Total score (green) (Y axis) obtained by each study patient (X axis) in the connective tissue disfunction assessment questionnaire. C) Patients age (X-axis) correlation with Beighton hypermobility score (Y-axis). A larger circle size indicates a greater number of patients with the same age and Beighton score. D) Total score obtained in connective tissue dysfunction assessment questionnaire (X-axis) correlation with number of rare damaging gene variants in connective tissue gene panel (Y-axis). A larger circle size indicates a greater number of patients with the same score and number of rare variants.
Figure Legend Snippet: A) Expression (Y axis) of connective tissue disorder genes (blue) in relation to all genes showing at least some expression within cervix (TPM>0) (light blue) (X axis). B) Beighton (pink) / Brighton (blue) / Total score (green) (Y axis) obtained by each study patient (X axis) in the connective tissue disfunction assessment questionnaire. C) Patients age (X-axis) correlation with Beighton hypermobility score (Y-axis). A larger circle size indicates a greater number of patients with the same age and Beighton score. D) Total score obtained in connective tissue dysfunction assessment questionnaire (X-axis) correlation with number of rare damaging gene variants in connective tissue gene panel (Y-axis). A larger circle size indicates a greater number of patients with the same score and number of rare variants.

Techniques Used: Expressing

We were the first to apply the Beighton/Brighton criteria to test the hypothesis linking the connective tissue dysfunction-driven nature of CI to genetics. While our analysis strengthened the association of CI with connective tissue pathways, further research is needed to explore the relationships between subclinical phenotypic expressions of connective tissue disorders and CI. Our next hypothesis is that the use of Beighton/Brighton criteria, along with the connective tissue dysfunction assessment questionnaire developed by our group, can serve as a predictive tool for CI/PTB, at least for a subset of patients. This investigation is currently underway in our group.
Figure Legend Snippet: We were the first to apply the Beighton/Brighton criteria to test the hypothesis linking the connective tissue dysfunction-driven nature of CI to genetics. While our analysis strengthened the association of CI with connective tissue pathways, further research is needed to explore the relationships between subclinical phenotypic expressions of connective tissue disorders and CI. Our next hypothesis is that the use of Beighton/Brighton criteria, along with the connective tissue dysfunction assessment questionnaire developed by our group, can serve as a predictive tool for CI/PTB, at least for a subset of patients. This investigation is currently underway in our group.

Techniques Used:



Similar Products

90
Genomics England connective disorder gene panel
Pathogenic / Likely pathogenic variants in <t> connective </t> tissue and related disorders gene panel and anamnesis of patients with cervical insufficiency.
Connective Disorder Gene Panel, supplied by Genomics England, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/connective disorder gene panel/product/Genomics England
Average 90 stars, based on 1 article reviews
connective disorder gene panel - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Invitae Inc connective tissue disorder gene panel
Pathogenic / Likely pathogenic variants in <t> connective </t> tissue and related disorders gene panel and anamnesis of patients with cervical insufficiency.
Connective Tissue Disorder Gene Panel, supplied by Invitae Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/connective tissue disorder gene panel/product/Invitae Inc
Average 90 stars, based on 1 article reviews
connective tissue disorder gene panel - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GeneDx Inc heritable disorders of connective tissue panel (57 genes (2019)
Pathogenic / Likely pathogenic variants in <t> connective </t> tissue and related disorders gene panel and anamnesis of patients with cervical insufficiency.
Heritable Disorders Of Connective Tissue Panel (57 Genes (2019), supplied by GeneDx Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/heritable disorders of connective tissue panel (57 genes (2019)/product/GeneDx Inc
Average 90 stars, based on 1 article reviews
heritable disorders of connective tissue panel (57 genes (2019) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Fulgent Genetics comprehensive connective tissue disorder gene panel
Pathogenic / Likely pathogenic variants in <t> connective </t> tissue and related disorders gene panel and anamnesis of patients with cervical insufficiency.
Comprehensive Connective Tissue Disorder Gene Panel, supplied by Fulgent Genetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/comprehensive connective tissue disorder gene panel/product/Fulgent Genetics
Average 90 stars, based on 1 article reviews
comprehensive connective tissue disorder gene panel - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Fulgent Genetics connective tissue disorder gene panel
FMR1 gene repeat testing in female patients presenting for heritable <t>connective</t> tissue disorders (HCTDs). Flow chart with details for patients who presented to the genetics clinic over a 3.5-year period. Next-generation sequencing results for genes included on commercially available connective tissue disorder testing panels were evaluated for 80 unrelated female patients. Unrelated female patients with no variants or variants of unknown significance (VUS) reported as ACMG-classified pathogenic, likely pathogenic or determined potentially pathogenic based on allele frequency, biological conservation, Grantham distance and damaging in silico predictions were followed up with FMR1 triplet repeat testing using an approved polymerase chain reaction (PCR), given a sufficient DNA sample was available.
Connective Tissue Disorder Gene Panel, supplied by Fulgent Genetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/connective tissue disorder gene panel/product/Fulgent Genetics
Average 90 stars, based on 1 article reviews
connective tissue disorder gene panel - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GeneDx Inc hereditary disorders of connective tissue gene panel
FMR1 gene repeat testing in female patients presenting for heritable <t>connective</t> tissue disorders (HCTDs). Flow chart with details for patients who presented to the genetics clinic over a 3.5-year period. Next-generation sequencing results for genes included on commercially available connective tissue disorder testing panels were evaluated for 80 unrelated female patients. Unrelated female patients with no variants or variants of unknown significance (VUS) reported as ACMG-classified pathogenic, likely pathogenic or determined potentially pathogenic based on allele frequency, biological conservation, Grantham distance and damaging in silico predictions were followed up with FMR1 triplet repeat testing using an approved polymerase chain reaction (PCR), given a sufficient DNA sample was available.
Hereditary Disorders Of Connective Tissue Gene Panel, supplied by GeneDx Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hereditary disorders of connective tissue gene panel/product/GeneDx Inc
Average 90 stars, based on 1 article reviews
hereditary disorders of connective tissue gene panel - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Pathogenic / Likely pathogenic variants in  connective  tissue and related disorders gene panel and anamnesis of patients with cervical insufficiency.

Journal: PLOS ONE

Article Title: Unravelling the genetic landscape of cervical insufficiency: Insights into connective tissue dysfunction and hormonal pathways

doi: 10.1371/journal.pone.0310718

Figure Lengend Snippet: Pathogenic / Likely pathogenic variants in connective tissue and related disorders gene panel and anamnesis of patients with cervical insufficiency.

Article Snippet: We compiled a connective disorder gene panel by accessing data from the PanelApp database’s homepage ( https://panelapp.genomicsengland.co.uk/ ), encompassing genes from EDS, OI, and Stickler syndrome panels (n = 102, ).

Techniques: Sequencing, RNA Expression

A) Expression (Y axis) of connective tissue disorder genes (blue) in relation to all genes showing at least some expression within cervix (TPM>0) (light blue) (X axis). B) Beighton (pink) / Brighton (blue) / Total score (green) (Y axis) obtained by each study patient (X axis) in the connective tissue disfunction assessment questionnaire. C) Patients age (X-axis) correlation with Beighton hypermobility score (Y-axis). A larger circle size indicates a greater number of patients with the same age and Beighton score. D) Total score obtained in connective tissue dysfunction assessment questionnaire (X-axis) correlation with number of rare damaging gene variants in connective tissue gene panel (Y-axis). A larger circle size indicates a greater number of patients with the same score and number of rare variants.

Journal: PLOS ONE

Article Title: Unravelling the genetic landscape of cervical insufficiency: Insights into connective tissue dysfunction and hormonal pathways

doi: 10.1371/journal.pone.0310718

Figure Lengend Snippet: A) Expression (Y axis) of connective tissue disorder genes (blue) in relation to all genes showing at least some expression within cervix (TPM>0) (light blue) (X axis). B) Beighton (pink) / Brighton (blue) / Total score (green) (Y axis) obtained by each study patient (X axis) in the connective tissue disfunction assessment questionnaire. C) Patients age (X-axis) correlation with Beighton hypermobility score (Y-axis). A larger circle size indicates a greater number of patients with the same age and Beighton score. D) Total score obtained in connective tissue dysfunction assessment questionnaire (X-axis) correlation with number of rare damaging gene variants in connective tissue gene panel (Y-axis). A larger circle size indicates a greater number of patients with the same score and number of rare variants.

Article Snippet: We compiled a connective disorder gene panel by accessing data from the PanelApp database’s homepage ( https://panelapp.genomicsengland.co.uk/ ), encompassing genes from EDS, OI, and Stickler syndrome panels (n = 102, ).

Techniques: Expressing

We were the first to apply the Beighton/Brighton criteria to test the hypothesis linking the connective tissue dysfunction-driven nature of CI to genetics. While our analysis strengthened the association of CI with connective tissue pathways, further research is needed to explore the relationships between subclinical phenotypic expressions of connective tissue disorders and CI. Our next hypothesis is that the use of Beighton/Brighton criteria, along with the connective tissue dysfunction assessment questionnaire developed by our group, can serve as a predictive tool for CI/PTB, at least for a subset of patients. This investigation is currently underway in our group.

Journal: PLOS ONE

Article Title: Unravelling the genetic landscape of cervical insufficiency: Insights into connective tissue dysfunction and hormonal pathways

doi: 10.1371/journal.pone.0310718

Figure Lengend Snippet: We were the first to apply the Beighton/Brighton criteria to test the hypothesis linking the connective tissue dysfunction-driven nature of CI to genetics. While our analysis strengthened the association of CI with connective tissue pathways, further research is needed to explore the relationships between subclinical phenotypic expressions of connective tissue disorders and CI. Our next hypothesis is that the use of Beighton/Brighton criteria, along with the connective tissue dysfunction assessment questionnaire developed by our group, can serve as a predictive tool for CI/PTB, at least for a subset of patients. This investigation is currently underway in our group.

Article Snippet: We compiled a connective disorder gene panel by accessing data from the PanelApp database’s homepage ( https://panelapp.genomicsengland.co.uk/ ), encompassing genes from EDS, OI, and Stickler syndrome panels (n = 102, ).

Techniques:

FMR1 gene repeat testing in female patients presenting for heritable connective tissue disorders (HCTDs). Flow chart with details for patients who presented to the genetics clinic over a 3.5-year period. Next-generation sequencing results for genes included on commercially available connective tissue disorder testing panels were evaluated for 80 unrelated female patients. Unrelated female patients with no variants or variants of unknown significance (VUS) reported as ACMG-classified pathogenic, likely pathogenic or determined potentially pathogenic based on allele frequency, biological conservation, Grantham distance and damaging in silico predictions were followed up with FMR1 triplet repeat testing using an approved polymerase chain reaction (PCR), given a sufficient DNA sample was available.

Journal: International Journal of Molecular Sciences

Article Title: Connective Tissue Disorders and Fragile X Molecular Status in Females: A Case Series and Review

doi: 10.3390/ijms23169090

Figure Lengend Snippet: FMR1 gene repeat testing in female patients presenting for heritable connective tissue disorders (HCTDs). Flow chart with details for patients who presented to the genetics clinic over a 3.5-year period. Next-generation sequencing results for genes included on commercially available connective tissue disorder testing panels were evaluated for 80 unrelated female patients. Unrelated female patients with no variants or variants of unknown significance (VUS) reported as ACMG-classified pathogenic, likely pathogenic or determined potentially pathogenic based on allele frequency, biological conservation, Grantham distance and damaging in silico predictions were followed up with FMR1 triplet repeat testing using an approved polymerase chain reaction (PCR), given a sufficient DNA sample was available.

Article Snippet: Approximately 75 genes are recognized to cause hereditary connective tissue disorders, as examined using a comprehensive connective tissue disorder gene panel with NGS performed at Fulgent Genetics.

Techniques: Next-Generation Sequencing, In Silico, Polymerase Chain Reaction